Initial product targets include:
Formulations for IV and oral administration with general anti-degenerative disease action
IV and oral medicine with anti-metastases effect to be used prior and after surgical tumor removal procedures
IV and oral medicine for treatment of various blood cancers and solid malignant tumors
IV and oral medicine to prevent local and general ageing and strengthen immune system.
5. New anti-viral and anti-bacterial compositions initially focused to fight hepatitis C, Herpes type 1 and type 2 and Staphylococcus aureus.
We are also developing new a isotope selective line:
6. VV- food supplements
7. VV- dietary products
8. VV- cosmetics